Wednesday, March 16, 2022 2:38:19 PM
In any case, unless your wife is working in an academic medical institution (an assertion you did NOT make), doing statistical research on patient compliance, any "data" now is too early and inadequate for extrapolation to any conclusions.
As far as the unfortunate side effects, that's a reality for many patients with a variety of diseases. Each patient makes his/her own decisions if the benefit is worth it. At this point alternatives are inferior to Lupkynis, and LN does not spontaneously disappear. The consequences of not treating the disease is catastrophic.
Recent AUPH News
- Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 • Business Wire • 11/15/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 09:47:34 PM
- Aurinia to Participate in Jefferies London Healthcare Conference • Business Wire • 11/14/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2024 12:20:36 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2024 12:05:46 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 11:17:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 11:13:58 AM
- Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth • Business Wire • 11/07/2024 11:10:00 AM
- Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development • Business Wire • 11/07/2024 11:00:00 AM
- Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 • Business Wire • 10/30/2024 08:05:00 PM
- Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 • Business Wire • 10/11/2024 10:00:00 AM
- Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis • Business Wire • 09/24/2024 12:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:56:55 PM
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference • Business Wire • 09/13/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:08:25 PM
- Aurinia Announces Board Restructuring • Business Wire • 09/12/2024 08:05:00 PM
- Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial • Business Wire • 09/05/2024 10:00:00 AM
- Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 08/28/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:06:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 10:07:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:03:38 AM
- Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results • Business Wire • 08/01/2024 10:00:00 AM
- Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 • Business Wire • 07/19/2024 10:00:00 AM
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 07/02/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:28 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM